Profile data is unavailable for this security.
About the company
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
- Revenue in JPY (TTM)3.59tn
- Net income in JPY197.39bn
- Incorporated1925
- Employees47.35k
- LocationTakeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
- Phone+81 332782111
- Fax+81 332782000
- Websitehttps://www.takeda.com/
More ▼
Mergers & acquisitions
| Acquired company | 4502:TYO since announced | Transaction value |
|---|---|---|
| Adaptate Biotherapeutics Ltd | 18.84% | -- |
Data delayed at least 20 minutes, as of Aug 12 2022 07:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck KGaA | 2.87tn | 453.36bn | 3.26tn | 62.77k | 24.68 | 3.15 | 4.79 | 1.16 | 7.61 | 7.61 | 48.18 | 59.70 | 0.4562 | 1.97 | 5.02 | 347,266.90 | 7.24 | 5.00 | 9.21 | 6.60 | 62.23 | 63.17 | 15.86 | 12.09 | 0.8173 | 24.58 | 0.312 | 9.16 | 12.28 | 5.56 | 53.75 | 13.40 | 10.88 | 9.04 |
| Astellas Pharma Inc | 1.35tn | 118.21bn | 3.79tn | 14.52k | 32.64 | 2.47 | 17.50 | 2.80 | 63.96 | 63.96 | 733.49 | 844.44 | 0.5714 | 1.74 | 3.37 | 93,087,110.00 | 5.00 | 7.94 | 6.93 | 10.93 | 79.31 | 78.89 | 8.74 | 12.82 | 1.11 | -- | 0.1713 | 47.16 | 3.73 | -0.2375 | 2.90 | -10.72 | 9.46 | 8.02 |
| HALEON PLC | 1.60tn | 242.93bn | 4.55tn | 22.80k | 17.21 | 0.9663 | -- | 2.62 | 0.1624 | 0.1624 | 1.07 | 2.89 | -- | -- | -- | 432,719.30 | -- | -- | -- | -- | 62.76 | -- | 15.68 | -- | 2.85 | 457.60 | 0.2888 | -- | -3.51 | -- | 21.40 | -- | -- | -- |
| Takeda Pharmaceutical Co Ltd | 3.59tn | 197.39bn | 6.19tn | 47.35k | 31.05 | 0.9607 | 7.78 | 1.72 | 126.39 | 126.39 | 2,296.99 | 4,085.66 | 0.2688 | 1.36 | 4.52 | 75,862,610.00 | 1.48 | 1.86 | 1.73 | 2.24 | 67.75 | 68.85 | 5.50 | 6.98 | 0.7485 | 3.53 | 0.4215 | 123.94 | 11.61 | 15.56 | -38.81 | 14.89 | 10.68 | 0.00 |
| Chugai Pharmaceutical Co Ltd | 1.21tn | 389.01bn | 6.27tn | 7.66k | 15.79 | 4.70 | -- | 5.20 | 236.46 | 236.46 | 732.88 | 794.74 | 0.8311 | 1.96 | 4.71 | 157,319,400.00 | 26.82 | 16.07 | 32.40 | 19.41 | 66.08 | 61.17 | 32.26 | 23.47 | 3.08 | -- | 0.00 | 44.38 | 27.04 | 15.25 | 41.10 | 41.41 | 14.88 | 34.40 |
| Bayer AG | 6.62tn | 580.60bn | 7.02tn | 101.91k | 12.03 | 1.34 | 6.06 | 1.05 | 4.31 | 4.31 | 49.22 | 38.70 | 0.398 | 1.71 | 3.47 | 485,331.80 | 3.51 | -1.37 | 4.71 | -1.77 | 61.89 | 59.99 | 8.82 | -3.73 | 0.8376 | 5.45 | 0.5388 | -- | 6.48 | 4.76 | 106.42 | -23.20 | 0.2547 | -5.52 |
Data as of Aug 12 2022. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
19.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 29 Jul 2022 | 68.06m | 4.30% |
| BlackRock Fund Advisorsas of 01 Jul 2021 | 51.07m | 3.23% |
| The Vanguard Group, Inc.as of 05 Aug 2022 | 39.18m | 2.48% |
| Daiwa Asset Management Co. Ltd.as of 29 Jul 2022 | 31.19m | 1.97% |
| Nikko Asset Management Co., Ltd.as of 05 Aug 2022 | 30.74m | 1.94% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 23.31m | 1.47% |
| BlackRock Japan Co., Ltd.as of 30 Jun 2021 | 23.22m | 1.47% |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 04 Aug 2022 | 15.14m | 0.96% |
| Geode Capital Management LLCas of 10 Aug 2022 | 12.24m | 0.77% |
| Canada Pension Plan Investment Boardas of 31 Mar 2022 | 11.62m | 0.73% |
More ▼
Data from 31 Dec 2021 - 30 Jun 2022Source: FactSet Research Systems Inc.
